poisar

Stocks · News reference

BioVie Announces New Clinical and Biomarker Findings from Phase 2 ADDRESS-LC Trial of Bezisterim

Fiscal.ai

BioVie Inc. presented new clinical and biomarker data from its Phase 2 ADDRESS-LC trial of bezisterim at the 4th Long COVID International Conference.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Fiscal.ai

    BioVie Reports 3Q 2026 Financial Results

    BioVie Inc. reported its third-quarter 2026 financial results, noting a wider quarterly loss driven by increased research and development expenses for its Long COVID program.